Sheet I of I

FORM PTO-1449 Commerce		U.S. Department of			Attorney Docket No.: UM-06192		Scrial No.: 09/867,930		
(Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (The Several Sheets If Nacronal)					Applicant: Blake J. Roessler et al.				
(Use Several Sheets If Neccessary) (37 CFR § 1.98(b))					Filing Date: 05/30/01	Group Art Unit:			
U.S. PATENT DOCUMENTS									
Examiner	Cite	Serial / Patent	Ionus Bata						
Initials	P 140. Maine;		ant / Patentee	Class Subclass Filing Da		Date			
Ju		5,595,978		, , , , , , , , , , , , , , , , , , , ,	······································			 	
Y-I	2	5,475,096						<u> </u>	
17	3	5,270,163						<u> </u>	
(A)	4	5,718,91.4			· · · · · · · · · · · · · · · · · · ·			Ł	
FOREIGN PATENTS OR PUBLISHED FOREIGN PATIENT APPLICATIONS									
		Document Number	Publication Date	Country / Patent Office		Class	Subclass	Translation	
1//						Class	SHOCISES	Yes	No
1/2	5	WO 94/08605	28 April 1994		PCT			<u> </u>	
15	- 6	WO 99/60012	25 Nov 1999		PCT				
	7	WO 99/21533	6 May 1999		PCT			<u> </u>	
2	·	OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)							
Ship	- 8	Roberton, Nature Biotechnology, 15:209 [1997]							
	9	Joel L. Zatz, Skin Permeation: fundamental and application, Allured Pub. Co., Wheaton, IL, 1993, Chapter 4 'In vitro Methods for Measuring Skin Permeation', pgs 93-111, and see Example 5)							
	10	Rieger, in "Pharmaceutical Dosage Forms: Disperse Systems, Vol. 1, Licherman, Rieger and Banker, Eds., Marcel Dekker, Inc., New York, NY, 1988, p. 285							
	11	Osborne et al., Pharmaceutical Technology, pgs 58-60, [Nov. 1997]							
	12	Rosoff, in Pharmaceutical Dosage Porms: Disperse Systems, Vol. 1, Lieberman, Riegar and Banker, Eds., Marcel Dekker, Inc., New York, NY, 1988, p. 245							
	13	Tomalia, Advanced Materials 6:529 [1994]							
	14	Tomalia et al., Angew, Chem. Int. Bd. Engl., 29:138 [1990]							
	15	Pennington et al., Allment Pharmacol. Ther., 1995							
	16	Raczka, et al., Gene Ther., 5:1333 [1998]							
	17	Sant et al., Hum. Gene Ther., 9:2735 [1998]							
	18	Niemicc, et al., J. Pharm Sci., 86:(6)701-708 [1997]							
	19	Yu et al., J. Invest. Dermatol., 112:370-375 (1999)							
	20	Fan et al., Nat. Biotechnology, 17:870-872, [1999]							
	21	Nuovo G.J., "PCR in situ Hybridization", Raven Press, New York, pp. 54-245 (1994)							
	22	Foreman et al., J. Clin. Invest., 99:2971-2978 (1997)							
	23	Haveroos et al. N. Engl. J. Med 312:1518 [1985]							
	24	Robbins et al. "Basic Pathology" p. 286 (W. B. Saunders Co., 2d ed. 1976)							
	25	Schmalfuss et al., Journal of Controlled Release, 46:279-285 (1997)							
77	26	Delgado-Charto et al., European Journal of Pharmaceutics And Biopharmaceutics, 43:37-42 (1997)							
X 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1									
Buardiner: The Considered: 9-30-03:									
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									